Histone deacetylase inhibitors (HDACi) have limited but significant clinical activity in human acute myelogenous leukemia (AML). Although it is well established that HDACi can induce histone acetylation and gene expression, the mechanism by which these agents exert their antileukemia effect is not well understood. Since the antileukemia effect of HADCi is at least partially mediated via induction of apoptosis, we hypothesized that combining an HDACi with a proapoptotic agent could enhance their antileukemia activities. Here, we report that the combination of an HDACi with BH3 mimetic GX15-070 results in synergistic antileukemia activity by inducing both apoptosis and autophagy. These results are of significance as suggest that this combination should be tested in patients with leukemia and that the role of autophagy in leukemia therapy needs to be studied further. 
INTRODUCTION
Small molecule inhibitors of histone deacetylases (HDAC) are a class of relatively novel therapeutic agents with clinical activity in both lymphoma 1 and leukemia. 2, 3 Although the mechanisms of action of HDAC inhibitors (HDACi) are not completely understood, the clinical anticancer activity of HDACi has been traditionally thought to be mediated in part through induction of histone acetylation, resulting in reactivation of aberrantly suppressed genes, leading to inhibition of proliferation, induction of apoptosis and cell differentiation. 4 Multiple HDACis are in clinical development, 1, 5 and vorinostat, a hydroxamic acid derivative, is approved in the US for patients with cutaneous lymphoma. 6 MGCD0103, an isotype-specific small molecule HDACi targeting HDAC isotypes 1, 2, 3, and 11, has been demonstrated to be orally bioavailable with significant in vitro activity against a broad spectrum of human cancers, including leukemia. 3 This agent has also been shown to be safe and have potential clinical activity in patients with advanced leukemia. 3 Historically, HDACi have been shown to have limited but significant single agent clinical activity in leukemia. 3 These results have led to the hypothesis that combination strategies may be the optimal way to use HDACis. GX15-070 (obatoclax) is a novel Bcl-2 homology domain-3 (BH3)
mimetic, that has been demonstrated to induce apoptosis in acute myeloid leukemia (AML) cells Because induction of apoptosis plays an important role in the anti-leukemia effect of HDACis, 4 we hypothesized that blocking anti-phosphate dehydrogenase (GAPDH) was used as internal control.
Statistical Analysis
Analysis of the effect of the combination was performed using a two-term tumor repopulation model. 9, 10, 11 Synergy detection of the drugs on primary leukemia cells was analyzed using the Bliss independence model.
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RESULTS
HDACis and GX15-070 synergistically inhibit cell proliferation in multiple AML cell lines
We first evaluated the anti-leukemia effect of HDACis in combination with GX15-070 in leukemia cell lines. In human AML cell lines HL-60, THP1 and U937, three days exposure to the combination of MGCD0103 (600 nM) and GX15-070 (200 nM) reduced cell viability more effectively than single drug treatment (supplemental Fig. 1A, 1B and 1C) . We then analyzed potential synergistic effect between MGCD0103 and GX15-070 in HL-60 and THP1 cells using a two-term synergy model.
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Analysis using this model requires cell viability to be calculated at multiple drug concentrations (as indicated in Table 1 ) and at multiple time points (24, 48, 72 and 96 hr). For each combination at different concentration levels, the interactive index was calculated using cell viability data from four time points. Results from this analysis indicated that in HL-60 and THP1 cells, interactive indexes from all different concentration combinations were below 0.4 (Table 1A and 1B), indicating a strong synergistic antiproliferative effect between MGCD0103 and GX15-030.
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Two-term synergy analysis was also performed in HL-60 cells using another HDACi, vorinostat, and GX15-070. A synergistic effect (interactive index < 0.4) at most of the concentrations analyzed was also observed (Table 1C) . These results indicate that combining HDACi with BH3 mimetic GX15-070 results in synergistic cytocoxicity on AML cells. Therefore we analyzed the induction of apoptosis with the two drug combination. HL-60 cells were treated with MGCD0103 (600 nM) and GX15-070 (200 nM) alone or in combination for 72 hrs. As shown in Fig. 1A , while MGCD0103 and GX15-070 induced modest levels of apoptosis in HL-60 cells, the two drug combination increased the fraction of apoptotic cells significantly. Similar results were observed in three independent experiments (Fig. 1B) . Apoptosis at different time points (day 2, 3 and 4) was also monitored, and similar results were observed (supplemental Fig. 1D ). Further, after 48 hrs of drug treatment, we observed enhanced activation of caspase 3 in MGCD0103/ GX15-070 combination treated cells (Fig 1C) , accompanied by increased cleavage of Poly (ADP-ribose) polymerase (PARP) (Fig 1C) . 15, 16 Significant induction of apoptosis and caspase 3 activation were also observed in HL-60 cells treated with vorinostat/ GX15-070 combination (supplemental Fig. 2A and 2B ). These results suggest that induction of apoptosis contributes to the HDACi and GX15-070 combination mediated antileukemia effect.
Combining HDACi and GX15-070 promotes autophagy in AML cells
Autophagy, also called type II programmed cell death, has been reported to contribute to the cytotoxicity mediated by single agent HDACi and GX15-070 in multiple malignancies. 17, 18, 19 Since the role of autophagy in chemotherapy-induced cell death is still controversial, it is of importance to examine if autophagy was induced by the two drug combination in this study, and if so, to define the effect of autophagy on the cytotoxicity led by this specific drug combination in treated with MGCD0103/ GX15-070 and vorinostat/ GX15-070 combination ( Fig. 2A) . A low level of LC3-II induction compared to the effect with the two drug combination treated cells was also detected in cells treated with GX15-070 alone ( Fig. 2A) . We also observed increased levels of conjugated Atg5-Atg12, a protein complex involved in autophagosome formation, 22 particularly in cells treated with MGCD0103/ GX15-070 combination ( Fig. 2A) .
We then used electron microscopy (EM) to examine the ultrastructural morphology of treated 2B ). Under higher magnification, we observed that those vesicles had double or multiple membrane boundaries (Fig. 2B ), a feature of autophagosomes.
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In contrast, no autophgosome was observed in GX15-070 or MGCD0103 single drug treated cells ( Fig. 2B and supplemental Fig. 3 ). Of importance, about 60% of non-apoptotic cells after the treatment with GX15-070 alone exhibited expanded endoplasmic reticulum (ER) (Fig. 2B) . Processing of LC3 to LC3-II can also be induced by ER expansion-associated but autophagy-independent mechanisms, 26 which may explain the slight increase of LC3-II in cells treated with GX15-070 alone ( Fig. 2A) .
To evaluate the role of autophagy in the antileukemia effect of the combination of MGCD0103
and GX15-070, we analyzed the effect of chloroquine (CQ), a known inhibitor of autophagy. viability by approximate two fold (Fig. 2C ), the addition of CQ to the combination of MGCD0103
and GX15-070 increased relative cell viability approximately 5 fold (Fig. 2C) . Furthermore, addition of CQ with the two drug combination resulted in decreased levels of LC3-II (Fig. 2D) . In contrast, level of LC3-II in GX15-070 alone treated cells was not reduced by the addition of CQ (Fig. 2D ). These results suggest that autophagy is specifically induced by the two drug combination, and plays a positive role in the cytotoxic effect of the combination.
Calpain activity positively regulates HDACi/ GX15-070 combination induced apoptosis and autophagy
We then investigated potential molecular mechanisms involved in the synergistic cytotoxic effect observed between HDACi and GX15-070. The apoptosis-inducing effect of GX15-070 has been shown to be mediated through BH3 domain containing proapoptotic proteins such as Bak and
Bax, that are released by GX15-070 from interacting antiapoptotic partners. Calcium-dependent cysteine protease (calpain) has been implicated in both apoptotic and autophagic cell death, 25, 26, 27 including HDACi induced apoptosis.
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To examine whether calpain activity contributes to the cytotoxicity induced by the two drug combination, we studied the effect (Fig. 3D) . Similar induction of Grp78 in cells treated with vorinostat/ GX15-070 combination was also observed (Supplemental Fig. 4C ). Grp upregulation confirmed the induction of ER stress by GX15-070. Since ER stress, and its progression into cell death, has been positively associated with Grp levels, the higher induction of Grp78 and Grp94 with the two drug combination treated cells (Fig. 3D) , we hypothesized that calpain induction could activate caspase 12/ caspase 4 signaling. This would promote GX15-070 induced ER stress to progress to cell death.
We analyzed levels of activated caspase 4 by Western blot and found it to be upregulated in MGCD0103/ GX15-070 combination treated cells, but not in single agent treated cells (Fig. 3D) .
Furthermore, caspase 4 activation, as well as induction of Grps, with the two drug combination were both repressed by the addition of calpain inhibitor PD15060 (Supplemental Fig. 4D ). These results strongly support our hypothesis and suggest that calpain promoted ER stress to cell death transition is an important mechanism for the synergistic cytotoxic effect observed between these two drugs. To further examine this hypothesis and the role of caspase 4, we studied the effect of caspase 4 inhibitor Z-LEVD-FMK on the two drug combination mediated cytotoxicity.
Addition of 10 μM of Z-LEVD-FMK caused 2-fold increase of viability in cells treated with MGCD0103/ GX15-070 combination, whereas no obvious effect was observed in MGCD0103 or GX15-070 single drug treated cells (Fig. 4A) . Furthermore, the addition of Z-LEVD-FMK repressed the induction of active caspase 3 in two drug combination treated cells (Fig. 4B) . Only a slight decrease of LC3 II was observed in these cells (Fig. 4B) . These results support the importance of calpain-caspase 4 signaling in the synergistic cytotoxic effect of the two drug combination.
Combination treatment of MGCD0103 and GX15-070 in primary AML cells
To study the clinical potential of MGCD0103 and GX15-070 combination in AML, we evaluated its antiproliferative effect in primary mononuclear peripheral blood leukemia cells. Patient characteristics are shown in supplemental Table 1 . Using trypan blue analysis, MGCD0103/GX15-070 combination induced stronger cytotoxicity in AML primary cells compared to single drug treatment (Fig. 5A ). Of importance, the combination had no obvious cytotoxic effect on normal control primary cells using the same assay (Fig. 5B) . Analysis of synergy using the Bliss model 12 indicated that the two-drug combination had synergistic cytotoxic effects in 5 out of 8 AML primary cells (#1, 2, 4, 6, and 7, figure 5A ). Consistent with the cell line data, we observed significant induction of apoptosis by MGCD0103/ GX15-070 combination in AML primary cells accompanied by enhanced caspase-3 activation ( Fig. 5C and   5D ). Of importance, we also observed accumulation of LC3-II, indicative of autophagy (Fig. 5D ).
DISCUSSION
In this study, we demonstrate that HDACi MGCD0103 or vorinostat in combination with the BH3 domain mimetic GX15-070 have synergistic antileukemia activity in AML. Although individually both HDACi and GX15-070 have been reported to induce growth arrest and apoptosis in human cancer cells, 3, 15 in this study a synergistic cytotoxic effect between these two types of agents occurred at concentrations in the nanomolar range. This is important as the IC50 of MGCD0103
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on We also demonstrate that the synergistic antileukemia effect observed is accompanied by activation of both apoptosis and autophagy, and that both of them, including autophagy, these results indicate that both autophagic death as well as induction of apoptosis by autophagy contribute to the synergistic antileukemia effect observed here.
In this study, we also demonstrate that calpain activity plays an important role in the synergistic cytotoxicity of HDACi/ GX15-070 combination. Calpain activity has been implicated at multiple levels in apoptosis and autophagy induction through a wide range of proteolysis substrates, in both caspase dependent and independent fashion.
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Particularly with the two drug combination our data indicates that one essential mechanism for the effect of calpain relates to the transition from GX15-070-induced ER stress to cell death. This is partially mediated by caspase 4. While calpain inhibitor PD15060 decreased both apoptosis (cleaved PARP) and autophagy (LC3-II) at a comparable level, caspase 4 inhibitor Z-LEVD-FMK had a more significant effect on repressing the major apoptotic signaling mediator caspase 3 than on repressing autophagy marker LC3-II. This result suggests that the major signals mediated by caspase 4 activation are pro-apoptotic. The signal for calpain activated ER stress to autophagy transition still needs to be determined. We also noticed that calpain inhibitor PD15060 could not completely restore cell viability, which implies that other calpain activity independent cell death mechanisms are induced by the two drug combination.
Of importance, ER stress has also been known to activate calpain activity through mechanism independent of expression induction. 
